CSP-2503

In today's world, CSP-2503 is a topic that has gained great relevance in all areas of society. From politics to technology, culture and economics, CSP-2503 has significantly impacted the way we live and relate. Over the years, CSP-2503 has sparked passionate debates and brought about profound changes in the way we approach different aspects of our daily lives. In this article, we will explore the different facets of CSP-2503 and analyze its influence in different areas, in order to better understand its impact on today's society.

CSP-2503
Clinical data
ATC code
  • none
Identifiers
  • 2-hexahydropyrrolopyrazine-1,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H26N4O2
Molar mass378.476 g·mol−1
3D model (JSmol)
  • O=C4N5CCCC5C(=O)N(CN3CCN(c2c1ccccc1ccc2)CC3)C4
  • InChI=1S/C22H26N4O2/c27-21-15-25(22(28)20-9-4-10-26(20)21)16-23-11-13-24(14-12-23)19-8-3-6-17-5-1-2-7-18(17)19/h1-3,5-8,20H,4,9-16H2 checkY
  • Key:CTZWGZSINBFHFD-UHFFFAOYSA-N checkY
  (verify)

CSP-2503 is a potent and selective 5-HT1A receptor agonist, 5-HT2A receptor antagonist, and 5-HT3 receptor antagonist of the naphthylpiperazine class.[1] First synthesized in 2003, it was designed based on computational models and QSAR studies.[2][3] In rat studies, CSP-2503 has demonstrated anxiolytic effects, and thus has been suggested as a treatment for anxiety in humans with a multimodal mechanism of action.[1]

See also

References

  1. ^ a b Delgado M, Caicoya AG, Greciano V, et al. (March 2005). "Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors". European Journal of Pharmacology. 511 (1): 9–19. doi:10.1016/j.ejphar.2005.01.032. PMID 15777774.
  2. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2003). "Design and synthesis of S-(−)-2-methyl]-1,4-dioxoperhydropyrrolopyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist". Bioorganic & Medicinal Chemistry Letters. 13 (8): 1429–32. doi:10.1016/S0960-894X(03)00160-4. PMID 12668005.
  3. ^ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2005). "Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors". Journal of Medicinal Chemistry. 48 (7): 2548–58. doi:10.1021/jm048999e. PMID 15801844.